Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients".
作者信息
Floyd James S, Psaty Bruce M
机构信息
Cardiovascular Health Research Unit, University of Washington, Seattle, 98101, USA.
出版信息
Arch Intern Med. 2012 Oct 8;172(18):1412-14. doi: 10.1001/archinternmed.2012.4306.
Abstract
摘要
相似文献
1
Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients".药物治疗的观察性比较效果研究：高质量答案还是重要临床问题？：对“两种β受体阻滞剂在高血压患者中的比较效果”的评论
Arch Intern Med. 2012 Oct 8;172(18):1412-14. doi: 10.1001/archinternmed.2012.4306.
2
Comparative effectiveness of 2 β-blockers in hypertensive patients.两种β受体阻滞剂对高血压患者的比较疗效
Arch Intern Med. 2012 Oct 8;172(18):1406-12. doi: 10.1001/archinternmed.2012.4276.
3
Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.钙通道阻滞剂与其他类抗高血压药物治疗既往有中风和/或冠状动脉疾病的高血压患者的疗效：一项系统评价和荟萃分析。
Am J Ther. 2017 Jan/Feb;24(1):e68-e80. doi: 10.1097/MJT.0000000000000369.
4
The case for beta-blockers as first-line antihypertensive therapy.β受体阻滞剂作为一线抗高血压治疗的依据。
J Hypertens Suppl. 1992 Jun;10(3):S21-7.
5
Calcium antagonists and beta-blockers: impact on cardiovascular and cerebrovascular events.
Clin Cornerstone. 2004;6(4):18-27. doi: 10.1016/s1098-3597(04)80075-9.
6
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers.血管紧张素原M235T多态性与接受ACE抑制剂或β受体阻滞剂治疗的高血压患者发生心肌梗死和中风的风险
Eur J Hum Genet. 2007 Apr;15(4):478-84. doi: 10.1038/sj.ejhg.5201789. Epub 2007 Feb 14.
7
The Role of Beta-Blockers in the Treatment of Hypertension.β受体阻滞剂在高血压治疗中的作用
Adv Exp Med Biol. 2017;956:149-166. doi: 10.1007/5584_2016_36.
8
beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke.β1和β2肾上腺素能受体基因变异、β受体阻滞剂的使用与心肌梗死和中风风险
Am J Hypertens. 2008 Mar;21(3):290-6. doi: 10.1038/ajh.2007.71. Epub 2008 Jan 24.
9
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.β受体阻滞剂引起的心率降低与高血压患者心脏保护作用的关系
J Am Coll Cardiol. 2008 Oct 28;52(18):1482-9. doi: 10.1016/j.jacc.2008.06.048.
10
Beta-blockers in hypertensive and coronary heart disease.β受体阻滞剂在高血压和冠心病中的应用
Arch Intern Med. 1996 Jun 24;156(12):1267-76.
本文引用的文献
1
Comparative effectiveness of 2 β-blockers in hypertensive patients.两种β受体阻滞剂对高血压患者的比较疗效
Arch Intern Med. 2012 Oct 8;172(18):1406-12. doi: 10.1001/archinternmed.2012.4276.
2
The evolving role of β-adrenergic receptor blockers in managing hypertension.β肾上腺素能受体阻滞剂在高血压治疗中的作用演变。
Can J Cardiol. 2012 May;28(3):334-40. doi: 10.1016/j.cjca.2012.04.001.
3
Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.氯噻酮与氢氯噻嗪降低心血管事件的比较：系统评价和网络荟萃分析。
Hypertension. 2012 Jun;59(6):1110-7. doi: 10.1161/HYPERTENSIONAHA.112.191106. Epub 2012 Apr 23.
4
When should we believe nonrandomized studies of comparative effectiveness?何时应采信比较有效性的非随机研究？
Clin Pharmacol Ther. 2011 Dec;90(6):764-6. doi: 10.1038/clpt.2011.243.
5
Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.在比较效果研究中最小化因适应症混杂导致的偏倚：限制的重要性。
JAMA. 2010 Aug 25;304(8):897-8. doi: 10.1001/jama.2010.1205.
6
Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.荟萃分析：β受体阻滞剂剂量、心率降低与心力衰竭患者的死亡情况
Ann Intern Med. 2009 Jun 2;150(11):784-94. doi: 10.7326/0003-4819-150-11-200906020-00006.
7
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.类似随机试验那样分析的观察性研究：绝经后激素治疗与冠心病的应用
Epidemiology. 2008 Nov;19(6):766-79. doi: 10.1097/EDE.0b013e3181875e61.
8
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
9
Recent trials in hypertension: compelling science or commercial speech?
JAMA. 2006 Apr 12;295(14):1704-6. doi: 10.1001/jama.295.14.1704.
10
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.β受体阻滞剂仍应作为原发性高血压治疗的首选药物吗？一项荟萃分析。
Lancet. 2005;366(9496):1545-53. doi: 10.1016/S0140-6736(05)67573-3.
Zotero 插件